NYSE:CBT - Cabot Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$65.67 -1.05 (-1.57 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$65.67
Today's Range$65.62 - $66.71
52-Week Range$50.56 - $68.63
Volume209,692 shs
Average Volume340,787 shs
Market Capitalization$4.12 billion
P/E Ratio19.15
Dividend Yield1.98%
Beta1.35
Cabot logoCabot Corporation operates as a specialty chemicals and performance materials company. The company offers carbon black, a form of elemental carbon used to enhance the physical properties of the systems and applications in which it is incorporated; and rubber blacks for use as a rubber reinforcing agent and performance additive in tires, hoses, belts, extruded profiles, and molded goods. It also provides compounds of carbon black and rubber primarily for tire applications; and cesium formate, a drilling and completion fluid for use in high pressure and high temperature oil and gas well construction. In addition, the company offers specialty grades of carbon black used in inks, coatings, plastics, adhesives, toners, batteries, and displays applications; masterbatch and conductive compound products for use in automotive, industrial, packaging, consumer products, and electronics industries; inkjet colorants used in the inkjet printing applications; and fumed silica, fumed alumina, and dispersions for automotive, construction, microelectronics, batteries, and consumer products industries, as well as aerogel, a hydrophobic, silica-based particle for use in various thermal insulation and specialty chemical applications. Further, it provides activated carbon products used for the purification of water, air, food and beverages, pharmaceuticals, and other liquids and gases; as a chemical carrier; and as a colorant or a decolorizing agent. The company sells its products primarily through distributors and sales representatives in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Cabot Corporation was founded in 1882 and is headquartered in Boston, Massachusetts.

Receive CBT News and Ratings via Email

Sign-up to receive the latest news and ratings for CBT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Miscellaneous chemical products
Sub-IndustryCommodity Chemicals
SectorBasic Materials
SymbolNYSE:CBT
CUSIP12705510
Phone617-345-0100

Debt

Debt-to-Equity Ratio0.47
Current Ratio1.67
Quick Ratio1.07

Price-To-Earnings

Trailing P/E Ratio19.15
Forward P/E Ratio16.02
P/E Growth1.57

Sales & Book Value

Annual Sales$2.72 billion
Price / Sales1.49
Cash Flow$5.8844 per share
Price / Cash11.16
Book Value$25.73 per share
Price / Book2.55

Profitability

EPS (Most Recent Fiscal Year)$3.43
Net Income$241 million
Net Margins-6.14%
Return on Equity15.83%
Return on Assets7.29%

Miscellaneous

Employees4,500
Outstanding Shares61,820,000
Market Cap$4,124.66

Cabot (NYSE:CBT) Frequently Asked Questions

What is Cabot's stock symbol?

Cabot trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBT."

How often does Cabot pay dividends? What is the dividend yield for Cabot?

Cabot declared a quarterly dividend on Monday, July 16th. Shareholders of record on Friday, August 31st will be given a dividend of $0.33 per share on Friday, September 14th. This represents a $1.32 annualized dividend and a yield of 2.01%. The ex-dividend date of this dividend is Thursday, August 30th. View Cabot's Dividend History.

How will Cabot's stock buyback program work?

Cabot announced that its board has authorized a share repurchase program on Monday, July 16th 2018, which authorizes the company to repurchase $400,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 10.3% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board of directors believes its shares are undervalued.

How were Cabot's earnings last quarter?

Cabot Corp (NYSE:CBT) announced its earnings results on Monday, May, 7th. The specialty chemicals company reported $1.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.00 by $0.04. The specialty chemicals company earned $818 million during the quarter, compared to analysts' expectations of $746.30 million. Cabot had a positive return on equity of 15.83% and a negative net margin of 6.14%. Cabot's revenue was up 20.6% on a year-over-year basis. During the same quarter last year, the company earned $0.87 earnings per share. View Cabot's Earnings History.

When is Cabot's next earnings date?

Cabot is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Cabot.

What price target have analysts set for CBT?

7 brokerages have issued 1-year target prices for Cabot's shares. Their forecasts range from $57.00 to $82.00. On average, they expect Cabot's stock price to reach $72.8333 in the next twelve months. This suggests a possible upside of 10.9% from the stock's current price. View Analyst Ratings for Cabot.

What is the consensus analysts' recommendation for Cabot?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabot in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Cabot?

Cabot saw a increase in short interest during the month of June. As of June 15th, there was short interest totalling 1,256,070 shares, an increase of 87.0% from the May 31st total of 671,818 shares. Based on an average daily volume of 571,185 shares, the short-interest ratio is presently 2.2 days. Approximately 2.1% of the shares of the company are short sold. View Cabot's Current Options Chain.

Who are some of Cabot's key competitors?

Who are Cabot's key executives?

Cabot's management team includes the folowing people:
  • Mr. Sean D. Keohane, Pres, CEO & Director (Age 51)
  • Mr. Brian A. Berube, Sr. VP & Gen. Counsel (Age 56)
  • Mr. Nicholas S. Cross, Exec. VP, Pres of Performance Chemicals segment & Pres of EMEA region (Age 57)
  • Mr. Hobart C. Kalkstein, Sr. VP, Pres of Reinforcement Materials Segment & Pres of Americas Region (Age 48)
  • Mr. Patrick M. Prevost, Advisor & Director (Age 63)

Has Cabot been receiving favorable news coverage?

Media coverage about CBT stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cabot earned a media sentiment score of 0.10 on Accern's scale. They also assigned media headlines about the specialty chemicals company an impact score of 45.03 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Cabot's major shareholders?

Cabot's stock is owned by many different of institutional and retail investors. Top institutional investors include Cabot Wellington LLC (0.56%), Deprince Race & Zollo Inc. (0.49%), Assenagon Asset Management S.A. (0.46%), Foundry Partners LLC (0.34%), Peregrine Capital Management LLC (0.21%) and Bank of Montreal Can (0.08%). Company insiders that own Cabot stock include Brian A Berube, Eduardo E Cordeiro, Gottberg Friedrich Von, Hobart Kalkstein, James Patrick Kelly, Michael M Morrow, Nicholas S Cross, Patrick M Prevost and Sean D Keohane. View Institutional Ownership Trends for Cabot.

Which institutional investors are selling Cabot stock?

CBT stock was sold by a variety of institutional investors in the last quarter, including Deprince Race & Zollo Inc., Cabot Wellington LLC, Municipal Employees Retirement System of Michigan, Fox Run Management L.L.C., CenturyLink Investment Management Co and Bank of Montreal Can. Company insiders that have sold Cabot company stock in the last year include Brian A Berube, Gottberg Friedrich Von, Hobart Kalkstein, James Patrick Kelly, Nicholas S Cross, Patrick M Prevost and Sean D Keohane. View Insider Buying and Selling for Cabot.

Which institutional investors are buying Cabot stock?

CBT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Foundry Partners LLC, Xact Kapitalforvaltning AB, Peregrine Capital Management LLC, State of Alaska Department of Revenue and Oakbrook Investments LLC. View Insider Buying and Selling for Cabot.

How do I buy shares of Cabot?

Shares of CBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cabot's stock price today?

One share of CBT stock can currently be purchased for approximately $65.67.

How big of a company is Cabot?

Cabot has a market capitalization of $4.12 billion and generates $2.72 billion in revenue each year. The specialty chemicals company earns $241 million in net income (profit) each year or $3.43 on an earnings per share basis. Cabot employs 4,500 workers across the globe.

How can I contact Cabot?

Cabot's mailing address is TWO SEAPORT LANE SUITE 1300, BOSTON MA, 02210. The specialty chemicals company can be reached via phone at 617-345-0100 or via email at [email protected]


MarketBeat Community Rating for Cabot (NYSE CBT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  301 (Vote Underperform)
Total Votes:  579
MarketBeat's community ratings are surveys of what our community members think about Cabot and other stocks. Vote "Outperform" if you believe CBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.